



Noxopharm 2023 AGM Chair's Address

Sydney, 16 November 2023: Innovative biotech company **Noxopharm Limited (ASX:NOX)** provides Noxopharm Non-Executive Chairman Mr Frederick Bart's address to the 2023 Annual General Meeting of Shareholders.

-ENDS-

About Noxopharm

Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance mRNA vaccines.

The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Chroma™ (oncology) and Sofra™ (inflammation, autoimmunity, and mRNA vaccine enhancement).

Noxopharm also has a major shareholding in US biotech company Nyrada Inc (ASX:NYR), which focuses on drug development for cardiovascular and neurological diseases.

To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries:

Julian Elliott

M: 0425 840 071

E: julian.elliott@noxopharm.com

Company Secretary:

David Franks

T: +61 2 8072 1400

E: David.Franks@automicgroup.com.au

Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.

Noxopharm 2023 AGM Chairman's Address

Fellow Shareholders,

Thank you for taking the time to be here today, and I am pleased to welcome you to Noxopharm's 2023 Annual General Meeting.

We appreciate the ongoing support of all our shareholders, whether they have been with us for several years or are relative newcomers to the company.

It has been a year of significant change for Noxopharm, and we are transforming the company with an evolved strategy and a new focus on our preclinical portfolio.

We believe this approach puts the company in the best possible position to make the most of its assets and create value for our shareholders.

Over the past few weeks, shareholders will have seen various announcements that show the progress we have made on our two preclinical platforms.

Dr Mautner will take you through these in more detail, but what is clear from all the recent news is that Noxopharm is heading in the right direction.

We are seeing the world of medicine change quickly, especially when it comes to RNA technology, and we want to make sure we are part of this new era.

We have advanced technology in this field that is relevant to vaccines as well as the development of new medicines for a wide range of diseases.

The company is also continuing to make good progress in its work in oncology, and advancing our pancreatic cancer program is one of our highest priorities.

Dr Mautner is leading a highly experienced management team, as well as a wider team of skilled professionals with outstanding scientific abilities.

We also have world class partners like the Hudson Institute and UNSW, and every year our relationship with those organisations grows deeper. They have tremendous expertise and years of experience in their respective fields, enabling us to benefit from their skills as we push forward with our work together.

On behalf of the Board, I would like to thank all of our shareholders for their ongoing support as this transformation journey continues. We hope that you can see the efforts that are being made on your behalf, and the choices that we are making to build a successful future for the company.

Yours sincerely,



Fred Bart

16 November 2023